In addition, CXCR4 and JUNB have been associated with poorer overall survival (OS) of early-stage breast cancer patients [31] and lower progression-free (PFS) and overall survival of NSCLC patients [30]. Here, CXCR4 is linked to non-small cell lung carcinoma.